Article
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Oncotarget - 8 Dec 2015
Kiessling Michael K, Curioni-Fontecedro Alessandra, Samaras Panagiotis, Atrott Kirstin, Cosin-Roger Jesus, Lang Silvia, Scharl Michael, Rogler Gerhard
Abstract excerpt
HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.